Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on June 25, 2024. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing requirements rather than financial performance.
Material Changes
The primary material event reported is the resolution of a minimum bid price deficiency. Previously, on May 12, 2023, the company received notice that its common stock closing bid price had been below the $1.00 per share minimum required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. On June 25, 2024, the company received notification from the Nasdaq Office of General Counsel that this deficiency had been cured and that the listing of its common stock would continue.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or new risk factors. The document confirms the continuation of the company's listing on The Nasdaq Capital Market following the cure of the bid price deficiency. A press release dated June 26, 2024, is included as an exhibit.
Investor Verification Checklist
- Verify the current trading price of JAGX to ensure it remains above the $1.00 minimum bid price threshold.
- Review the press release (Exhibit 99.1) for any additional details on the steps taken to cure the deficiency.
- Monitor future filings for any recurrence of listing deficiency notices.
- Check the company's most recent 10-Q or 10-K for actual financial performance metrics, as they are not included in this 8-K.